Liver Cancer News and Research RSS Feed - Liver Cancer News and Research

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Researchers discover new potential treatment target for liver cancer

Researchers discover new potential treatment target for liver cancer

Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer. [More]
High levels of p62 protein in liver linked to cancer recurrence

High levels of p62 protein in liver linked to cancer recurrence

Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. [More]
Research sheds light on potential impact of HCV treatment in preventing virus transmission

Research sheds light on potential impact of HCV treatment in preventing virus transmission

An international team of researchers has shed light on the potential impact of new drugs for hepatitis C virus (HCV). [More]
High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of a digestive hormone called secretin may play an important role in the management of certain chronic liver diseases, according to new research published in the journal Hepatology. These findings could result in new ways to treat cholestatic liver diseases, a condition that impairs the movement of bile, the fluid produced by the liver to digest fats. [More]
Clinical study shows sitagliptin drug not effective in treating NAFLD

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. [More]
MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Hepatitis B virus screening for Asian American adults can help prevent onset of liver diseases

Hepatitis B virus screening for Asian American adults can help prevent onset of liver diseases

A community-based hepatitis B virus screening effort led by UC Davis researchers found that targeted outreach to Asian American populations can identify groups at high risk for infection and direct them to appropriate follow-up care to help prevent the onset of liver diseases, including cancer. [More]
Increasing number of sickest liver transplant candidates delisted from wait list, study finds

Increasing number of sickest liver transplant candidates delisted from wait list, study finds

The sickest liver transplant candidates should be first in line when a donor liver becomes available, but transplant centers are increasingly removing these individuals from the waiting list, considering them "too sick to transplant," an analysis of nationwide transplant data finds. The study appears online as an "article in press" on the Journal of the American College of Surgeons website in advance of print publication. [More]
Resolving HBV infection does not reduce liver cancer risk

Resolving HBV infection does not reduce liver cancer risk

Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection was not associated with reduced rates of liver cancer. [More]
Cancer survivors at risk of death after organ transplant

Cancer survivors at risk of death after organ transplant

People who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer or develop a new cancer than organ recipients who did not previously have cancer, a new paper has found. However, the increased risk is less than that reported in some previous studies. [More]
Researchers reposition existing prazosin drug to combat glioblastoma

Researchers reposition existing prazosin drug to combat glioblastoma

Treatments available for glioblastoma—malignant brain tumors—have little effect. An international collaboration led by the Laboratoire Neurosciences Paris-Seine tested active ingredients from existing medications and eventually identified one compound of interest, prazosin, on these tumors. Not only did it seem to be effective in this type of cancer, but it also acted on a signaling pathway that is common with other cancers. [More]
Scientists discover new diagnostic marker for liver cancer

Scientists discover new diagnostic marker for liver cancer

Scientists may have discovered a significant new diagnostic marker for liver cancer, according to a paper published in the April 18 online issue of Nature Cell Biology. [More]
Scientists develop innovative technique to deliver cancer drugs deep into tumour cells

Scientists develop innovative technique to deliver cancer drugs deep into tumour cells

Scientists at Nanyang Technological University (NTU Singapore) have invented a new way to deliver cancer drugs deep into tumour cells. [More]
Johns Hopkins study suggests updated universal screening for hepatitis C virus

Johns Hopkins study suggests updated universal screening for hepatitis C virus

A review of blood samples for nearly 5,000 patients seen at The Johns Hopkins Hospital Emergency Department suggests that federal guidelines for hepatitis C virus (HCV) screening may be missing up to a quarter of all cases and argues for updated universal screening. [More]
HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness. [More]
New research shows type 2 diabetes as important risk factor for chronic liver disease

New research shows type 2 diabetes as important risk factor for chronic liver disease

People with type 2 diabetes are at greater risk of serious liver disease than those without the condition, new research has shown. [More]
Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Newcastle scientists and medics have developed a new type of genetic blood test that diagnoses scarring in the liver - even before someone may feel ill. [More]
Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals. [More]
Mount Sinai Hospital uses M1 LUMI Bead loaded with doxorubicin for liver cancer treatment

Mount Sinai Hospital uses M1 LUMI Bead loaded with doxorubicin for liver cancer treatment

An innovative cancer treatment made of luminescent chemotherapy-filled beads injected into tumors through the wrist is now available for patients with inoperable and difficult-to-treat liver cancer. [More]
Advertisement